SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligence platform (SOMAIPRO®), is pleased to announce that the recruitment of the Phase IIb clinical study with SOM3355 as a treatment for Huntington’s chorea has been completed.

After a a Phase IIa study where the patients confirmed the good safe profile and clinical benefit on choreic movements , SOM Biotech conducted a 12-weeks doubleblind, placebo-controlled dose-finding Phase IIb study, assessing the efficacy and safety of two dose regimens. Results are expected by the end of the year.

Click here to read the full press release.


Leave a Reply

Avatar placeholder

Your email address will not be published. Required fields are marked *